



Cite this: *J. Mater. Chem. B*, 2018, **6**, 6550

Received 8th May 2018,  
Accepted 1st June 2018

DOI: 10.1039/c8tb01215f

rsc.li/materials-b

## Rapid formulation of redox-responsive oligo- $\beta$ -aminoester polyplexes with siRNA *via* jet printing†

Tatiana Lovato,<sup>‡a</sup> Vincenzo Taresco,<sup>‡a</sup> Ali Alazzo,<sup>a</sup> Caterina Sansone,<sup>b</sup> Snjezana Stolnik,<sup>IDa</sup> Cameron Alexander<sup>ID\*<sup>a</sup></sup> and Claudia Conte<sup>ID\*<sup>ab</sup></sup>

Here we describe a rapid inkjet formulation method for screening newly-synthesised cationic materials for siRNA delivery into cancer cells. Reduction responsive oligo- $\beta$ -aminoesters were prepared and evaluated for their ability to condense siRNA into polyplexes through a fast inkjet printing method. A direct relationship between the oligomer structures and charge densities, and the final cell response in terms of uptake rate and transfection efficacy, was found. The oligo- $\beta$ -aminoesters were well-tolerated by the cancer cells, compared to conventional cationic polymers so far employed in gene delivery, and were as active in silencing of a representative luciferase gene.

## Introduction

Successful and practical gene therapies require consistent formulations which can be easily prepared, and which can effectively deliver nucleic acids to intracellular target sites.<sup>1,2</sup> In turn these formulations need nucleic acid carrier vehicles which are safe in human patients, and with the highest performance in terms of *in vivo* stability, cellular delivery and transfection efficiency.<sup>3</sup> Accordingly, combinations of advances in materials chemistry and pharmaceutical formulations are pre-requisites for nucleic acid therapeutics.<sup>4</sup>

To date, the formulation parameters for nucleic acid delivery have generally evolved from research lab-based protocols for preparing polymer–nucleic acid polyelectrolyte complexes, and these can be highly ‘operator-dependent’. In part this is due to the many variables important in the polycation carrier/nucleic acid polyanion association process, as the kinetics of polyelectrolyte complex formation are highly variable across concentration ranges, order and speed of addition.<sup>5–8</sup> As a consequence, methods to prepare, formulate and screen cationic polymers for nucleic acid delivery are required, and these protocols need to be rapid, use small quantities and be easily applicable across ranges of physical and chemical properties. The increasing use of printing methods for screening pharmaceutical materials is a potential

means by which polymer–nucleic acid complexes might be optimised for practical formulations.<sup>9–11</sup>

Concurrently, a very wide range of natural and synthetic cationic polymers have been explored as potential non-viral gene delivery systems, particularly for cancer treatment.<sup>1</sup> Amongst these materials, oligo- and poly( $\beta$ -aminoester)s (OBAEs and PBAEs) have emerged as promising candidates, as they are easy to synthesise and are biodegradable due to their hydrolysable ester backbones.<sup>12,13</sup> These materials are generally positively charged at physiological pH and thus are able to condense spontaneously with nucleic acids through electrostatic interactions. The main advantage of PBAEs compared to other conventional cationic materials is their significantly lower cytotoxicity, combined with their ability to transfect cells with high efficiency.<sup>14,15</sup> However, the molecular weight, the structure and the supramolecular architectures of polycations, including PBAEs, play a pivotal role in the final biological effect, influencing the cytotoxicity as well as the gene transfection activity.<sup>16–20</sup> For instance, it has been demonstrated that polycations with high molecular weight (MW) usually show appreciable cytotoxicities, even though their stronger condensation capacity toward nucleic acids tends to improve transfection potency compared to their lower molar mass analogues.<sup>21,22</sup> In addition, dependent on their ratio of primary, secondary and tertiary amines, OBAEs and PBAEs may display appropriate  $pK_a$  ranges to exploit the “proton sponge mechanism” thus enhancing escape of polyplexes and nucleic acids from endosomal compartments which in turn improves access to the targeted genes.<sup>18,23,24</sup> However, while highly stable polymer–DNA complexes are desirable during the initial stages of the delivery process, the release of the nucleic acid cargo is more rapid if the vector can be degraded into smaller, less charged, fragments. The hydrolysis of the polyester backbones in PBAEs in cellular fluids typically occurs on the time scale of

<sup>a</sup> Division of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, NG7 2RD, UK.  
E-mail: cameron.alexander@nottingham.ac.uk

<sup>b</sup> Drug Delivery Laboratory, Department of Pharmacy, University of Napoli Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.  
E-mail: claudia.conte@unina.it

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8tb01215f

‡ These authors contributed equally.



several hours to a few days, depending on the polymer structure, thus affecting the release of the gene cargoes and the final transfection effect. While it is possible to tune the degradation rate of the PBAE polymer *via* molar mass and monomer structure, it is also desirable to encode “on-demand” cargo release, such that very rapid dissociation of the nucleic acid can occur at the correct cellular region. This can be achieved by incorporating disulfide bonds in the polymer backbone, which can be cleaved in the reducing environments of certain intracellular milieu, thereby improved the efficiency of gene delivery.<sup>25,26</sup>

In this manuscript, we report the synthesis of a small range of redox responsive, cytocompatible oligo- $\beta$ -aminoesters (OBAEs) which are able to condense and transfect siRNA into cancer cells. Through a specific modulation of the molar ratio between the starting materials, we obtained OBAEs with different structures and positive charge densities, thus tuning their capabilities to interact with siRNA and elicit a subsequent biological response. Furthermore, we designed the OBAEs to have solubility properties allowing them to be formed into-siRNA polyplexes *via* an easy, fast and cheap inkjet technology. We considered inkjet printing to be particularly suitable for screening the formulations of biotherapeutics in this study as this technique is versatile, scalable and can deposit picolitre volumes of solution with high accuracy and reproducibility. The data together show that oligomeric cations and siRNA can be easily print-formulated into effective *in vitro* nucleic acid delivery systems.

## Experimental

### Materials

All solvents were of analytical or HPLC grade and purchased from Sigma or Fisher Scientific unless otherwise stated. Deuterated solvents were from Sigma. Acryloyl chloride, ethylene-dioxy-bis-ethylamine, triethylamine (TEA), dithiodiethanol, sodium chloride, potassium phosphate dibasic and potassium phosphate monobasic, sodium azide, sodium phosphate dibasic, ethidium bromide (EtBr), fluorescamine, polyethylenimine (PEI) (25 kDa, branched) calf thymus DNA and glutathione (GSH), were used as received from Sigma Aldrich. Luciferase siRNA (CCGCAAGAUCGCGAGAUAU) was provided by Eurogentec (UK). Luciferase Assay System with Reporter Lysis Buffer and CellTiter 96<sup>®</sup> Aqueous One Solution Cell Proliferation Assay (MTS) were provided by Promega (UK). Silencer<sup>™</sup> Cy<sup>™</sup>3-labeled Negative Control was provided by Thermo-fisher Scientific (UK).

### Synthesis and characterization of cationic oligo ( $\beta$ -amino ester)s

The synthesis of the oligo- $\beta$ -aminoester (OBAE) was *via* a two-step reaction, *i.e.* (1) the synthesis of disulfanediylbis(ethane-2,1-diyl) diacrylate and (2) the Michael addition reaction between disulfanediylbis(ethane-2,1-diyl) diacrylate and ethylenedioxy-bis-ethylamine.

(1) **Synthesis of disulfanediylbis(ethane-2,1-diyl)diacrylate (DSD).** Synthesis of DSD was carried out *via* a literature method with minor modifications.<sup>27</sup> Briefly, dithiodiethanol (10 g, 0.065 mol) was added to a round-bottom flask equipped with three-way stopcocks

connected to either a nitrogen line or a vacuum pump, and dried *via* azeotropic distillation with anhydrous toluene (3  $\times$  20 mL) under reduced pressure. After complete evaporation of toluene, anhydrous THF (20 mL) was added *via* a syringe under inert atmosphere. TEA (6.5 g, 0.065 mol) was added to the solution which was maintained at 4  $^{\circ}$ C during drop wise addition of acryloyl chloride (3.5 g, 0.039 mol). The solution was allowed to warm to room temperature under magnetic stirring and left to react overnight. The solution was finally filtered to remove the chloride salt of TEA and the crude product was recovered by evaporation of THF. The product was purified by passing through silica column chromatography using petroleum ether/ethyl acetate 90:10 as eluents to generate a soft solid (yield 85%).

ATR-IR:  $\nu$  (cm<sup>-1</sup>) 3449, 2978, 2874, 1725, 1634, 1620, 1513, 1454, 1408, 1371, 1223, 1177, 1045, 978, 911, 814, 663.

<sup>1</sup>H NMR (400 MHz, d<sup>6</sup>-DMSO, ppm):  $\delta_{\text{H}}$  3.01–3.03 (t, 2,  $J$  = 8 Hz, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 4.35–4.38 (t, 2,  $J$  = 4 Hz, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 5.95 (dd, 1,  $J$  = 4 Hz,  $J$  = 8 Hz, –OCOCHCH<sub>2</sub>), 6.17 (dd, 1,  $J$  = 8 Hz,  $J$  = 16 Hz, –OCOCHCH<sub>2</sub>), 6.36 (dd, 1,  $J$  = 4 Hz,  $J$  = 20 Hz, –OCOCHCH<sub>2</sub>).

<sup>13</sup>C NMR (400 MHz, d<sup>6</sup>-DMSO, ppm):  $\delta_{\text{C}}$  36.4 (s, 1, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 62.1 (s, 1, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 128.1 (s, 1, –OCOCHCH<sub>2</sub>), 131.8 (s, 1, –OCOCHCH<sub>2</sub>), 165.0 (s, 1, –OCOCHCH<sub>2</sub>).

(2) **Synthesis of oligo- $\beta$ -aminoesters (OBAEs).** For the Michael addition reaction, different amounts of DSD (0.76 mmol, 0.96 mmol, 1.15 mmol) dissolved in 1 mL of anhydrous DCM were added into a solution of ethylene-dioxy-bis-ethylamine (0.17 g, 1.15 mmol) in 1 mL of anhydrous DCM. The reaction was performed in the dark at 30  $^{\circ}$ C for 5 days under nitrogen. The final product was then dissolved in MeOH and precipitated into ice-cold diethyl-ether three times. Finally, the polymer was dried under vacuum overnight. The yield of the polymer was 72%.

ATR-IR:  $\nu$  (cm<sup>-1</sup>) 3269, 3070, 2865, 1643, 1551, 1494, 1457, 1355, 1295, 1099, 1024, 819, 755.

<sup>1</sup>H NMR (500 MHz, d<sup>6</sup>-DMSO, ppm):  $\delta_{\text{H}}$  2.50–2.53 (m, 2, –OCOCH<sub>2</sub>CH<sub>2</sub>–), 2.72–2.79 (m, 2, –NCH<sub>2</sub>CH<sub>2</sub>O–), 2.78–2.81 (t, 2,  $J$  = 15 Hz, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 2.94–3.04 (m, 2, –OCOCH<sub>2</sub>CH<sub>2</sub>–), 3.21–3.24 (m, 2, –OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 3.41–3.44 (m, 2, –OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 3.54–3.57 (m, 2, –NCH<sub>2</sub>CH<sub>2</sub>O–), 3.58–3.60 (m, 4, –OCH<sub>2</sub>CH<sub>2</sub>O–, –OCH<sub>2</sub>CH<sub>2</sub>O–), 3.61–3.63 (m, 2, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 8.27 (br, 3, –OCH<sub>2</sub>CH<sub>2</sub>NH<sub>3</sub><sup>+</sup>).

<sup>13</sup>C NMR (500 MHz, d<sup>6</sup>-DMSO, ppm):  $\delta_{\text{C}}$  32.4 (s, 1, –OCOCH<sub>2</sub>CH<sub>2</sub>–), 39.0 (s, 1, –OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>–), 41.5 (s, 2, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 44.3 (s, 1, –OCOCH<sub>2</sub>CH<sub>2</sub>–), 51.4 (s, 1, –NCH<sub>2</sub>CH<sub>2</sub>O–), 60.1 (s, 2, –SSCH<sub>2</sub>CH<sub>2</sub>O–), 69.4 (s, 2, –OCH<sub>2</sub>CH<sub>2</sub>O–, –OCH<sub>2</sub>CH<sub>2</sub>O–), 69.8 (s, 1, –OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>–), 70.0 (s, 1, –NCH<sub>2</sub>CH<sub>2</sub>O–), 170.3 (s, 2, –OCOCH<sub>2</sub>CH<sub>2</sub>–)  $m/z$  found [M – H]<sup>–</sup> (A): 2331; (B): 1434; (C): 560.

### Characterization of OBAE

<sup>1</sup>H-, <sup>13</sup>C-NMR, 2D-NMR (COSY, HSQC, HMBC) spectra were recorded at 25  $^{\circ}$ C on a Bruker Advance III 500 MHz spectrometer. All chemical shifts are reported in ppm ( $\delta$ ) relative to tetramethylsilane or referenced to the chemical shifts of residual solvent resonances. Multiplicities are described with the following abbreviations: s = singlet, br = broad, d = doublet, t = triplet,



m = multiplet, dd = doublet of doublets. MestReNova 6.0.2 copyright 2009 (Mestrelab Research S. L.) was used for analysing the spectra.

FT-IR spectra were recorded with an attenuated total reflection spectrophotometer (Agilent Technologies Cary 630 FTIR) equipped with a diamond single reflection ATR unit. Spectra were acquired with a resolution of  $4\text{ cm}^{-1}$  by co-adding 32 interferograms, in the range  $4000\text{--}650\text{ cm}^{-1}$ .

IR analysis were performed by using SpectraGryph version1.0.

Mass spectra were carried out using a Micromass LCT ToF with electrospray ionization and OpenLynx software.

### Fluorescamine assays for amine content determination

The intensity of fluorophore resulting from the reaction of fluorescamine with primary amine was measured using a Cary Eclipse Fluorescence Spectrophotometer and glycine as standard. To a 2 mL sample of polymer solution (concentration  $10\text{ }\mu\text{g mL}^{-1}$ , in borate buffer pH 8.7), 0.5 mL of fluorescamine in acetone ( $0.3\text{ mg mL}^{-1}$ ) were added and vortexed for 10 seconds. After incubation of the reagents in the dark for 20 minutes, the emission from the resulting solution was measured at a wavelength of 480 nm using an excitation wavelength of 385 nm against a blank of borate buffer with fluorescamine.

### Buffer capacity of OBAE

The buffer capacity of OBAE was determined by acid–base titration. Acid–base titration was performed using a Fisherbrand pH meter with a Hydrus 600 electrode. Briefly, 0.5 mg of PBAE were dissolved in 1 mL of NaCl 0.1 M and the pH of the polymer solution was adjusted with 0.1 M HCl to 3. Then, the solution was titrated with NaOH 0.1 M and the pH value of solution was measured.

The buffering capacity was defined as the percentage of the protonated amine groups from pH 7.4 to 5.0 and calculated according to the following equation:

$$\text{Buffer capacity (\%)} = 100(\Delta V\text{NaOH} \times 0.1\text{ M})/N\text{ mol}$$

where,  $\Delta V\text{NaOH}$  is the volume of 0.1 M NaOH, which changes the pH of the polymer sample from 5 to 7.4, and  $N\text{ mol}$  is the total moles of amine groups in the sample.

For total amine content, the volume of NaOH required to ionize all the amine groups based on the first derivative analysis of titration curve was used and multiplied by the concentration (0.1 M). As the concentration of NaOH is the same, it can be removed from the above equation.

### Printing set-up and work flow conditions

Prior to dispensing the siRNA aqueous solutions into a 96-wellplate filled with 100  $\mu\text{L}$  of water solutions of OBAEs for each well, the target had to be defined. Firstly, the outer dimensions of the wellplate were added to the software scifLEXARRAYER (Scienion AG, version 2.09.002) followed by defining the number of wells, well distance, well depth and the spot area (area within the target designated for spotting). siRNA solutions were dispensed *via* a piezo electric inkjet printer (Sciflexarray S5, Scienion) through a 90  $\mu\text{m}$  orifice nozzle. Each droplet was dispensed with a rate of 30–40 drop per  $\mu\text{s}$  with sizes ranging in between

250 and 280 pL. Droplet volume was altered by tuning the values of the voltage (98–105 volt) and electrical pulse (45–55  $\mu\text{s}$ ). Images of the drop formation and droplet size were obtained using the printer software. The final spots were imaged using the Leica MZ16 stereomicroscope.

Depending on the siRNA/oligomer ratios to be reached, the number of drops per spot was adjusted accordingly. The nozzle was washed with Milli-Q water, in between each printing cycle, as part of the automated printing-washing loop. The nozzle was programmed to dispense the siRNA solutions into the well from a vertical distance of *circa* 10–20 mm from the well-plate, no contact between the nozzle tip and the water surface was allowed.

### Polyplexes characterization

The hydrodynamic diameter (DH), polydispersity index (PI) and zeta potential of polyplexes were determined on a Zetasizer Nano ZS (Malvern Instruments Ltd). A NP dispersion was diluted in Milli-Q water at intensity in the range  $10^4\text{--}10^6$  counts per s and measurements were performed at  $25\text{ }^\circ\text{C}$  on  $90^\circ$  angle. Results are reported as mean of three separate measurements of three different batches ( $n = 9$ )  $\pm$  standard deviation (SD). Morphology and shape of polyplexes were monitored through Atomic Force Microscopy (Bruker Dimension Fast Scan Bio).

siRNA complexation was confirmed by agarose gel retardation. Polyplexes containing 1  $\mu\text{g}$  of siRNA were loaded on 2% agarose gel in Tris–Acetate–EDTA (TAE) buffer and subjected to electrophoresis for 45 min at 70 V. siRNA bands were stained with EtBr and finally visualized with an UV illuminator.

### Ethidium bromide displacement assay

In this assay, calf thymus DNA ( $50\text{ }\mu\text{g mL}^{-1}$  in PBS) was incubated with ethidium bromide ( $2\text{ }\mu\text{g mL}^{-1}$ ) for 30 minutes. Thereafter, aliquots of 100  $\mu\text{L}$  were mixed with 100  $\mu\text{L}$  of polymer solutions at different concentrations. The samples were incubated under stirring for 30 minutes, and then the fluorescence intensity of DNA–ethidium bromide complexes was measured at a wavelength of 590 nm using an excitation wavelength of 520 nm.

### Cell culture

A549 lung cancer cells were obtained from the American Type Culture Collection, cultured at  $37\text{ }^\circ\text{C}$  in a humidified atmosphere containing 5%  $\text{CO}_2$  and grown continuously in DMEM supplemented with 10% FBS, 100 unit per mL penicillin and  $100\text{ }\mu\text{g mL}^{-1}$  streptomycin.

### Cell metabolic activity (viability) assay

A549 luciferase expressing cells ( $2 \times 10^4$ ) were placed in 96-well plates and cultured in 200  $\mu\text{L}$  of cell medium with or without FBS at 10%. After 24 h, cells were treated with free OBAEs in the concentration range  $0.005\text{--}5\text{ mg mL}^{-1}$ . As control, cells were treated as well as with an aqueous solution of free polyethylenimine (PEI) at the same concentration range. Cells treated with 0.1% (v/v) Triton-X 100 and fresh media were used as a positive and a negative control, respectively. After 24 h of incubation, cells were washed with PBS and treated with CellTiter 96<sup>®</sup> Aqueous One Solution Cell Proliferation Assay (MTS, Promega) (20  $\mu\text{L}$  per well). After further



incubation (3 h), the absorbance was read at 490 nm in a microplate reader (Tecan Platereader). The percentage of metabolic activity (%) was calculated according to the equation:

$$\text{Cell viability (\%)} = \frac{[(\text{OD sample} - \text{OD CTR+}) / (\text{OD CTR} - \text{OD CTR+})] \times 100}$$

### Transfection studies

For transfection studies, A549 luciferase expressing cells ( $5 \times 10^4$ ) were seeded into 24-well plates and cultured in 500  $\mu\text{L}$  of cell medium with FBS at 10%. After 24 h, the culture medium was replaced with 0.5 mL of fresh serum-free DMEM and treated with siRNA/OBAE polyplexes containing 1  $\mu\text{g}$  of siRNA/well. After 4 h of incubation, cells were washed three times with fresh medium in order to remove NPs and incubated again at 37  $^{\circ}\text{C}$  until 48 h. Finally, after transfection, luciferase activity was measured as RLU per mg protein using the luciferase assay system (Luciferase Assay System with Reporter Lysis Buffer, Promega) and BCA reagent (Sigma, UK).

### Uptake and endolysosomal escape

A549 luciferase expressing cells ( $2 \times 10^4$ ) were seeded in eight well chamber slides (Nunc, Thermo Fisher Scientific Inc., UK) and cultured in 300  $\mu\text{L}$  of cell medium with FBS at 10%. After 24 h, the culture medium was replaced with 0.3 mL of fresh serum-free DMEM and treated with 10 mg  $\text{mL}^{-1}$  of polyplexes formed by OBAEs and Cy3-siRNA at 10 : 1 polymer/siRNA weight ratio. After 4 h of incubation, cells were washed three times with fresh medium without Phenol Red and treated with LysoTracker Green DND-26 (Invitrogen Life Technologies, UK) containing media (100 nM) and then with DAPI (Invitrogen Life Technologies, UK) containing media (1  $\mu\text{g mL}^{-1}$ ) for 10 minutes at rt in the dark according to the manufacturer's specifications. Live cells were finally imaged through confocal microscopy (Zeiss LSM 700 Confocal Laser Scanning Microscope equipped with argon and HeNe lasers and a 40 $\times$ /1.2 NA water objective). Zen 2009 image Software was utilized for image processing.

### Statistical analysis

Unless otherwise stated, all data are shown as mean  $\pm$  standard deviation (SD), two-way analysis of variance (ANOVA) was applied for comparison of three or more group means (Tukey's multiple comparisons test). *P* value of  $<0.05$  was considered statistically significant. \*\*\*\*, \*\*\*, \*\*, and \* display  $p < 0.0001$ ,  $p < 0.001$ ,  $p < 0.01$ , and  $p < 0.05$ , respectively. GraphPad Prism 6 software was used for data analysis.

## Results and discussion

The initial focus for the study was to develop oligomers and polymers with properties suitable for rapid condensation of siRNA *via* inkjet printing and also triggered degradation properties. Accordingly, OBAEs were synthesized through Michael-type addition reaction between the acrylate groups of a disulfanediybis(ethane-2,1-diyl)diacrylate (DSD), and the terminal amino groups of ethylene-dioxy-bis-ethylamine.

The bioreducible disulfide-containing monomer DSD was synthesized through reaction of dithiodiethanol with acryloyl chloride and its structure confirmed by  $^1\text{H}$ ,  $^{13}\text{C}$  and 2D-NMR spectroscopy (Fig. S1, ESI $^\dagger$ ), as previously reported.<sup>27</sup> Then, DSD was employed in a *aza*-Michael addition reaction with the diamine ethylene-bioxy-bis-ethylamine, using different molar ratios of the starting materials (1:1, 1:1.25 and 1:1.5 DSD/ethylene-dioxy-bis-ethylamine ratio), thus yielding three different OBAEs (A, B and C, respectively). The ratios of the diacrylate and diamine were varied in order to modulate the final properties of the products. The higher diamine ratio was intended to produce a lower molar mass product and the 1:1 mixture the highest molar mass, which we anticipated would affect their 'printability'.

The condensation reactions were allowed to proceed for 5 days at 30  $^{\circ}\text{C}$  (Fig. 1). All the OBAEs synthesized were characterized through  $^1\text{H}$ ,  $^{13}\text{C}$  and 2D-NMR spectroscopy in  $d^6$ -DMSO (Fig. 2 and Fig. S2, S3, ESI $^\dagger$ ), Electron Spray Ionization (ESI) mass spectra (Fig. S5, ESI $^\dagger$ ) and FT-ATR-IR spectroscopy (Fig. S6, ESI $^\dagger$ ).

The  $^1\text{H}$ -NMR spectra of the three OBAEs synthesised gave very similar NMR spectra (Fig. 2 and Fig. S2A, S3A, ESI $^\dagger$ ). In particular, the resonances of the protons of the methyl groups at  $\delta = 2.25$ –2.27 ppm and  $\delta = 2.90$ –3.02 ppm (no. 5 and 6 respectively) confirmed the presence of a secondary amine in the OBAE backbone. The signal of the protons of the methyl groups adjacent to the disulfide bond at  $\delta = 3.41$ –3.43 ppm (no. 1) demonstrated the integrity of the disulfide bond after the reaction with ethylene-dioxy-bis-ethylamine. The lack of a resonance at  $\delta = 5.00$ –7.00 ppm associated with the vinyl protons denoted complete conversion of the terminal double bonds during the Michael addition reaction and the presence of a peak at  $\delta = 8.27$  ppm indicated a protonated primary amine at the chain terminus. However, it is possible to notice in Fig. S4 (ESI $^\dagger$ ) that the relative intensities of the signals of the proton adjacent to the di-sulphide bond (yellow circle) and the protons in proximity of the newly formed secondary amine (pink circle) changes. This change was not proportional to the variation in feed ratio of ethylene-dioxy-bis-ethylamine and could be explained by hydrolysis of the ester bond on inter/intra molecular amidation reaction occurring between  $\text{NH}_2$  and ester bond in line with  $^{13}\text{C}$  and 2D-NMR spectroscopy.

Due to the intrinsic chemical similarity in terms of functionalities, the three OBAEs showed essentially superimposable ATR-IR spectra as evidenced in Fig. S6 (ESI $^\dagger$ ). FT-ATR-IR spectra of the OBAEs showed a broad signal at 3250  $\text{cm}^{-1}$ , typical of the stretching resonance of an extended H-bonded network of both secondary and primary amine groups, in contrast to the




Fig. 1 Synthetic reaction of OBAEs.








Fig. 2 Characterization of OBAE C. (A)  $^1\text{H}$  NMR spectrum; (B)  $^{13}\text{C}$  NMR spectrum collected for 6 h; (C)  $^1\text{H}$ – $^1\text{H}$  COSY NMR spectrum and (D)  $^1\text{H}$ – $^{13}\text{C}$  HSQC NMR spectrum. Spectra recorded at 500 MHz in  $\text{d}_6$ -DMSO.

two sharp peaks at  $3400\text{ cm}^{-1}$  and  $3200\text{ cm}^{-1}$  in the spectrum of ethylene-dioxy-bis-ethylamine starting material due to primary amine functionality. The formation of a secondary amine was also confirmed by the shift of the N–H bending resonance from  $1595\text{ cm}^{-1}$  to  $1551\text{ cm}^{-1}$ . The frequency of the C=O stretching band moved from  $1725\text{ cm}^{-1}$  in the spectrum of DSD to  $1643\text{ cm}^{-1}$  in the spectrum of OBAs, as a result of the Michael addition reaction. Additionally, as for DSD, OBAs showed a weak transition at around  $670\text{ cm}^{-1}$  characteristics of C–S stretching.

ESI mass spectroscopy suggested molar masses ranging from 560 Da (OBAE C, Fig. S5C, ESI $^\dagger$ ) to 1434 Da (OBAE B, Fig. S5B, ESI $^\dagger$ ) and 2331 Da (OBAE A, Fig. S5A, ESI $^\dagger$ ) for the OBAs synthesized, as expected from a step growth polymerization

under the conditions employed. GPC data were difficult to interpret, perhaps owing to adsorption of the oligomers to the columns used, and thus additional characterisation methods were required. The number of reactive primary amines on the OBAs were determined by fluorescamine assays, and the total number of basic amines was determined by acid–base titration (Fig. S7, ESI $^\dagger$ ). The values for the amine content of the oligomers were A:  $0.85\text{ mmol g}^{-1}$ ; B  $1.39\text{ mmol g}^{-1}$  and C:  $3.27\text{ mmol g}^{-1}$ . These results were in excellent agreement with fluorescamine assay data for OBAE C (also  $3.27\text{ mmol g}^{-1}$ ), but less well-correlated for A and B, most likely due to their lower overall amine content.

Taken together, these data suggested a series of different materials, for which the theoretical structures derived from the most common fragments detected in mass spectrometry are shown in Fig. 3.

Prior papers describing poly(beta-aminoesters) have suggested structures deduced from the molar ratios of the functional groups of the monomers used, and have not always taken into account the potential formation of branches in the polymeric structure, even if diacrylate/diamine monomers have been used.<sup>28,29</sup> In our case, we aimed for a variety of structures, including possible branching, such that the oligomers might condense with siRNA in different architectures during the ink-jet printing process.

We next explored the possibility to inkjet print the oligomers with siRNA. This method has been exploited for biomaterials and drug discovery,<sup>30–32</sup> cell based therapies<sup>33</sup> and for screening amorphous solid dispersions<sup>11</sup> but to date only a few examples have been demonstrated for the formulation of micro- and nano-drug delivery systems.<sup>34–36</sup> We thus screened the capability of the OBAs to condense with siRNA by ink-jet printing in a 96-well plate starting from aqueous stock solutions of polymers and siRNA at different concentrations (Fig. 4). The amount of siRNA used was minimised by adoption of this method. For example, it was possible to perform 100 different experiments, with nine repeats of each OBAE/siRNA polyplex formulation (at each explored ratio),




Fig. 3 Putative structures of the OBAs A, B and C based on the most common fragments from mass spectrometry and amine titration data.






Fig. 4 Schematic illustration of OBAE/siRNA polyplexes formation through ink-jet printing technique.

with as little as 800 ng of siRNA. The use of diluted solution of siRNA (0.01% w/v) allowed to work with ink formulations presenting low viscosity, close to the one of pure water (video as supporting data). By handling inks with such low viscosity, well-defined droplets were produced. Consequently, it has been simple to prevent the unwanted production of satellite droplets, as showed in Fig. S9 (ESI<sup>†</sup>).

The full set of polyplexes was prepared in less than 20 min by adopting a fully automated loop, and with the further advantage of storing all the samples in the compact space of a single 96-well plate. The properties of the obtained polyplexes were compared with those made by conventional manual nanoprecipitation routes in order to confirm the potential and the reproducibility of this technique in the formation of drug delivery systems (Fig. S8A and B, ESI<sup>†</sup>). Polyplexes at different polymer/siRNA ratios were characterized in terms of size and polydispersity index through dynamic light scattering (DLS) (Fig. 5A). AFM analysis were also carried out, as shown for the OBAE C/siRNA polyplex at polymer/siRNA 10:1 weight ratio to better clarify the morphology, size and shape of the polyplexes. As evident in Fig. 5B, the OBAE/siRNA polyplexes were of spherical shape with size distributions in line with DLS data (between 200 nm and 500 nm).

The OBAs were found to exhibit different behaviours in terms of complexation with siRNA, as expected from their chemical structures and charge densities. In particular, OBAE A formed polyplexes ranging from 600 to 1000 nm characterized by high polydispersity indexes, depending on the amount of siRNA condensed. In contrast, OBAE C showed the best performance in terms of complexation, thus forming polyplexes from 200 to 450 nm with an uniform size distribution in all the siRNA concentrations tested.

The ability of the OBAs to form complexes with siRNA was investigated by agarose gel retardation (Fig. 6A) and ethidium bromide displacement assays (Fig. 6B). For the latter experiment,




Fig. 5 Characterization of OBAE/siRNA polyplexes. (A) Size and polydispersity index of OBAE/siRNA polyplexes at different polymer/siRNA weight ratios. (B) AFM images of OBAE C/siRNA polyplex at polymer/siRNA 10:1 weight ratio.




Fig. 6 (A) siRNA condensation by A, B and C at different polymer/siRNA weight ratios as evaluated by the gel retardation assay. N represents naked siRNA. (B) Ethidium bromide displacement assay. (C) Stability of OBAE C/siRNA polyplex at polymer/siRNA 10:1 weight ratios incubated in GSH 10 mM for 2 h.

calf thymus DNA was incubated with ethidium bromide for 30 min and thereafter mixed with polyplexes at different polymer/siRNA ratio. Ethidium bromide displacement was monitored by fluorescence spectroscopy. In addition, experiments were carried out to simulate the behaviour of the polyplexes in an intracellular reducing environment. Accordingly, polyplexes were dispersed in buffer solutions containing GSH (10 mM) and their size was monitored throughout 2 h of incubation. As apparent from Fig. 6C, a marked change in the median diameters of particles in solution from ~100 nm to ~10 nm was observed after addition of GSH, indicating disassembly of the polyplexes following reductive stimulus.

The obtained results combined with the gel retention assays, confirmed the different condensation capabilities of OBAs with



siRNA, in line with their different charge densities. In particular, it was evident from the dye displacement and gel retardation assays that the siRNA binding affinity per unit mass of OBAEs increased from sample A to sample C, and that the polyplexes were disassembled in reducing environments. No significant difference in siRNA condensation capacity of OBAEs *via* jet printing or manual method was found (Fig. S8C, ESI†).

The biological effects of the OBAE/siRNA polyplexes were investigated in A549 lung cancer cells. In this study we designed disulfide-linked OBAEs of intermediate molar mass such that the oligomers would have sufficient charge to associate with siRNA during transit across cellular barriers, but also have an ability to depolymerise rapidly in the reducing intracellular environments to fragments which would have low affinity for siRNA and also low cytotoxicity.<sup>16,37,38</sup> We therefore compared the effects of free OBAEs on the metabolic activities of A549 cells to those of the widely-used transfection agent branched PEI (25 kDa) after 4 h of treatment (Fig. 7A). Gene knockdown was then evaluated in an A549 cell line which constitutively expressed luciferase, using an anti-luciferase siRNA (CCGCAAG AUCCGCGAGAUAU) and a control siRNA with a non-coding (scrambled) sequence. Cells were incubated for 4 h with OBAE/siRNA polyplexes at OBAE/siRNA 10 : 1 weight ratio (10  $\mu\text{g mL}^{-1}$  of polyplexes) (Fig. 7B).

The A549 cells retained  $\sim 80\%$  metabolic activity even when treated with the higher concentration of OBAEs and were significantly less toxic compared to PEI, which caused cell death at similar concentrations. As expected from the different

siRNA binding properties of the OBAEs developed, a progressive increase in transfection efficiency was observed from oligomer A to oligomer C, with an overall knockdown activity of OBAE C greater than that of PEI at the same weight ratio (Fig. 7B), independently by the preparation method (Fig. S8D, ESI†). The intracellular transport of the polyplexes was probed in preliminary confocal microscopy experiments using a fluorescent Cy3-tagged siRNA (Fig. 8). Inspection of the micrographs indicated that a progressive increase in siRNA internalization occurred ranging from oligomer A to oligomer C at the same concentration and time frame, in line with the expected trend based on the transfection results.

The successful knockdown indicated that some of the polyplexes were able to escape to the reducing cytosolic regions where oligomer breakdown enabled delivery of the siRNA. Based on the previously described titration curves, the buffering capacities of the polymers were calculated to be 17, 24 and 56% for OBAE A, B and C respectively. Thus it was expected that OBAE C might be the most effective as an endosomal buffering agent to exploit the 'proton sponge' effect. As apparent from Fig. 9, a partial co-localization of the delivered siRNA with the lysosomes was found for OBAE C, suggesting that these complexes were initially trafficked to endolysosomal compartments. The subsequent enhanced knockdown achieved by these complexes was indicative that the OBAE C polyplexes were more stable in these regions compared to those of A and B, and were hence able to deliver siRNA more effectively following endo-lysosomal escape.

The data together indicated that the lowest molar mass OBAE was the most effective in terms of ease of formulation *via* ink-jet printing, and also in delivering siRNA to knock down the activity of luciferase. Based on NMR and mass spectrometry data, OBAE C was identified as the adduct of 2 ethylene-dioxy-bis-ethylamine monomers bridged by a single DSD unit, and would therefore have the highest number of basic amines per unit mass of the three OBAEs prepared. The titration data confirmed this assertion, and it was thus not surprising that OBAE C was the most effective of the candidates in siRNA condensation and polyplex formation. Our aim in this study was not to optimise the delivery systems, but to identify early in a synthesis/formulation cycle which, out of a pool of potential nucleic acid carriers, might be best from a printing and primary efficacy perspective. The fact that we were able to identify rapidly an oligo-beta-amino ester, which was as active as PEI




Fig. 7 (A) Cytotoxicity of free OBAEs and (B) *in vitro* luciferase siRNA transfection from polyplexes vs. free siRNA (ctr) in A549-luciferase expressing cells after 4 h of incubation. RLU = relative light units, a measure for luciferase expression. Results are expressed as mean  $\pm$  SD of three experiments. \*\*\*\* $P$  < 0.0001, \*\*\* $P$  < 0.001, \*\* $P$  < 0.01, \* $P$  < 0.05 two-way ANOVA test.





Fig. 8 Confocal images of A549-luciferase expressing cells after 4 h of incubation with 10  $\mu\text{g mL}^{-1}$  of polyplexes. (A) Uptake of OBAE/Cy3-siRNA polyplexes at 10 : 1 polymer/siRNA weight ratio. Cell nuclei were stained with DAPI (blue) and the images were acquired with 545 nm excitation and LP 560 nm spectral filters for Cy3-siRNA detection (red). (a) untreated cells, (b) naked siRNA, (c) OBAE A polyplexes, (d) OBAE B polyplexes, (e) OBAE C polyplexes. Zen 2009 image Software was utilized for image processing. Scale bar: 20  $\mu\text{m}$ .







**Fig. 9** Intracellular trafficking of OBAE C/Cy3-siRNA polyplexes at 10:1 polymer/siRNA weight ratio. (a) Nucleus stained with DAPI, (b) Cy3-siRNA emission (ex: 555 nm excitation, em: LP 560), (c) Lysotracker Green DND-26 emission (ex: 488 nm, em: SP 555), (d) merge. Zen 2009 image Software was utilized for image processing. Scale bar: 20  $\mu$ m.

in transfection but with much reduced effects on metabolic activity, using this method is indicative of its promise for future synthesis and formulation strategies.

## Conclusions

Here we have shown the synthesis and characterisation of redox responsive oligo- $\beta$ -aminoesters for siRNA delivery into cancer cells. Through an appropriate modulation of the molar ratio of the starting materials, we obtained oligo- $\beta$ -aminoesters with different structures and charge densities. These cationic materials were rapidly condensed with siRNA through a facile and versatile high-throughput inkjet method, thus forming polyplexes with different siRNA binding affinities as well as colloidal properties. The new OBAs showed reduced toxicity against cancer cells compared to the standard comparator PEI, yet retained a comparable high efficacy for transfection of siRNA in A549 cells. Future work will investigate the *in vivo* activities of these promising materials.

## Data access statement

All raw data created during this research are openly available from the corresponding authors [cameron.alexander@nottingham.ac.uk](mailto:cameron.alexander@nottingham.ac.uk) and [claudia.conte@unina.it](mailto:claudia.conte@unina.it) and at the University of Nottingham Research Data Management Repository (<https://rdmc.nottingham.ac.uk/>). All analyzed data supporting this study are provided as ESI† accompanying this paper.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Claudia Conte was supported by a fellowship by Associazione Italiana per la Ricerca sul Cancro (AIRC) co-funded by the European Union (iCARE/Marie Curie 2014). Tatiana Lovato thanks the EPSRC for a Doctoral Prize Fellowship. This work was supported by the Engineering and Physical Sciences Research Council grant numbers EP/H005625/1, EP/N03371X/

1 and a Royal Society Wolfson Research Merit Award (WM150086) to CA. We also thank Tom Booth, Paul Cooling, Esme Ireson and Christine Grainger-Boulby for technical support.

## References

- 1 Z. Zhou, X. Liu, D. Zhu, Y. Wang, Z. Zhang, X. Zhou, N. Qiu, X. Chen and Y. Shen, *Adv. Drug Delivery Rev.*, 2017, **115**, 115–154.
- 2 A. N. Zelikin, C. Ehrhardt and A. M. Healy, *Nat. Chem.*, 2016, **8**, 997–1007.
- 3 M. A. Islam, E. K. G. Reesor, Y. Xu, H. R. Zope, B. R. Zetter and J. Shi, *Biomater. Sci.*, 2015, **3**, 1519–1533.
- 4 A. Samanta and I. L. Medintz, *Nanoscale*, 2016, **8**, 9037–9095.
- 5 D. W. Bartlett and M. E. Davis, *Bioconjugate Chem.*, 2007, **18**, 456–468.
- 6 J. C. Kasper, D. Schaffert, M. Ogris, E. Wagner and W. Friess, *J. Controlled Release*, 2011, **151**, 246–255.
- 7 S. C. Semple, A. Akinc, J. X. Chen, A. P. Sandhu, B. L. Mui, C. K. Cho, D. W. Y. Sah, D. Stebbing, E. J. Crosley, E. Yaworski, I. M. Hafez, J. R. Dorkin, J. Qin, K. Lam, K. G. Rajeev, K. F. Wong, L. B. Jeffs, L. Nechev, M. L. Eisenhardt, M. Jayaraman, M. Kazem, M. A. Maier, M. Srinivasulu, M. J. Weinstein, Q. M. Chen, R. Alvarez, S. A. Barros, S. De, S. K. Klimuk, T. Borland, V. Kosovrasti, W. L. Cantley, Y. K. Tam, M. Manoharan, M. A. Ciufolini, M. A. Tracy, A. de Fougères, I. MacLachlan, P. R. Cullis, T. D. Madden and M. J. Hope, *Nat. Biotechnol.*, 2010, **28**, 172–176.
- 8 A. L. Troutier-Thuilliez, J. Thevenot, T. Delair and C. Ladaviere, *Soft Matter*, 2009, **5**, 4739–4747.
- 9 M. Sanna, G. Sicilia, A. Alazzo, N. Singh, F. Musumeci, S. Schenone, K. A. Spriggs, J. C. Burley, M. C. Garnett, V. Taresco and C. Alexander, *ACS Med. Chem. Lett.*, 2018, **9**, 193–197.
- 10 I. Louzao, B. Koch, V. Taresco, L. Ruiz-Cantu, D. J. Irvine, C. J. Roberts, C. Tuck, C. Alexander, R. Hague, R. Wildman and M. R. Alexander, *ACS Appl. Mater. Interfaces*, 2018, **10**, 6841–6848.
- 11 V. Taresco, I. Louzao, D. Scurr, J. Booth, K. Treacher, J. McCabe, E. Turpin, C. A. Laughton, C. Alexander, J. C. Burley and M. C. Garnett, *Mol. Pharmaceutics*, 2017, **14**, 2079–2087.





- 12 P. Mastorakos, C. Zhang, E. Song, Y. E. Kim, H. W. Park, S. Berry, W. K. Choi, J. Hanes and J. S. Suk, *J. Controlled Release*, 2017, **262**, 37–46.
- 13 S. Y. Tzeng, D. R. Wilson, S. K. Hansen, A. Quinones-Hinojosa and J. J. Green, *Bioeng. Transl. Med.*, 2016, **1**, 149–159.
- 14 D. G. Anderson, D. M. Lynn and R. Langer, *Angew. Chem.*, 2003, **42**, 3153–3158.
- 15 C. G. Zamboni, K. L. Kozielski, H. J. Vaughan, M. M. Nakata, J. Kim, L. J. Higgins, M. G. Pomper and J. J. Green, *J. Controlled Release*, 2017, **263**, 18–28.
- 16 A. A. Eltoukhy, D. J. Siegwart, C. A. Alabi, J. S. Rajan, R. Langer and D. G. Anderson, *Biomaterials*, 2012, **33**, 3594–3603.
- 17 S. Werth, B. Urban-Klein, L. Dai, S. Hobel, M. Grzelinski, U. Bakowsky, F. Czubyko and A. Aigner, *J. Controlled Release*, 2006, **112**, 257–270.
- 18 J. C. Sunshine, D. Y. Peng and J. J. Green, *Mol. Pharmaceutics*, 2012, **9**, 3375–3383.
- 19 F. Martello, M. Piest, J. F. Engbersen and P. Ferruti, *J. Controlled Release*, 2012, **164**, 372–379.
- 20 A. A. Y. Almulathanon, E. Ranucci, P. Ferruti, M. C. Garnett and C. Bosquillon, *Pharm. Res.*, 2018, **35**, 86.
- 21 P. Y. Teo, C. Yang, J. L. Hedrick, A. C. Engler, D. J. Coady, S. Ghaem-Maghami, A. J. T. George and Y. Y. Yang, *Biomaterials*, 2013, **34**, 7971–7979.
- 22 X. J. Deng, N. Zheng, Z. Y. Song, L. C. Yin and J. J. Cheng, *Biomaterials*, 2014, **35**, 5006–5015.
- 23 A. Akinc, M. Thomas, A. M. Klivanov and R. Langer, *J. Gene Med.*, 2005, **7**, 657–663.
- 24 A. Akinc and R. Langer, *Biotechnol. Bioeng.*, 2002, **78**, 503–508.
- 25 S. Y. Tzeng, B. P. Hung, W. L. Grayson and J. J. Green, *Biomaterials*, 2012, **33**, 8142–8151.
- 26 K. L. Kozielski, S. Y. Tzeng and J. J. Green, *Chem. Commun.*, 2013, **49**, 5319–5321.
- 27 C. Y. Hong, Y. Z. You, D. C. Wu, Y. Liu and C. Y. Pan, *J. Am. Chem. Soc.*, 2007, **129**, 5354–5355.
- 28 J. Kim, J. C. Sunshine and J. J. Green, *Bioconjugate Chem.*, 2014, **25**, 43–51.
- 29 A. A. Eltoukhy, D. Chen, C. A. Alabi, R. Langer and D. G. Anderson, *Adv. Mater.*, 2013, **25**, 1487–1493.
- 30 D. G. Anderson, S. Levenberg and R. Langer, *Nat. Biotechnol.*, 2004, **22**, 863–866.
- 31 E. A. Clark, M. R. Alexander, D. J. Irvine, C. J. Roberts, M. J. Wallace, S. Sharpe, J. Yoo, R. J. M. Hague, C. J. Tuck and R. D. Wildman, *Int. J. Pharm.*, 2017, **529**, 523–530.
- 32 A. B. M. Buanz, C. C. Belaunde, N. Soutari, C. Tuleu, M. O. Gul and S. Gaisford, *Int. J. Pharm.*, 2015, **494**, 611–618.
- 33 T. Xu, J. Rohozinski, W. X. Zhao, E. C. Moorefield, A. Atala and J. J. Yoo, *Tissue Eng., Part A*, 2009, **15**, 95–101.
- 34 T. Ehtezazi, N. M. Dempster, G. D. Martin, S. D. Hoath and I. M. Hutchings, *J. Pharm. Sci.*, 2014, **103**, 3733–3742.
- 35 S. Hauschild, U. Lipprandt, A. Rumpelcker, U. Borchert, A. Rank, R. Schubert and S. Forster, *Small*, 2005, **1**, 1177–1180.
- 36 N. Scoutaris, S. Ross and D. Douroumis, *Pharm. Res.*, 2016, **33**, 1799–1816.
- 37 H. Y. Xue, S. M. Liu and H. L. Wong, *Nanomedicine*, 2014, **9**, 295–312.
- 38 M. Breunig, U. Lungwitz, R. Liebl and A. Goepferich, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 14454–14459.

